TORONTO, ONTARIO--(Marketwired - Oct. 28, 2013) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company), today announced the appointment of William Rice, Ph.D. as its Chief Executive Officer and Chairman of the Board of Directors. Lorus specializes in targeting essential apoptosis pathways to deliver transformational cancer drugs, and Dr. Rice will guide the strategic and clinical missions of the Company.
"Dr. Rice is a biotech veteran with more than 20 years of leadership experience and a successful record of strategic, scientific and financing accomplishments. We are privileged to announce his addition to the Lorus team," said Jim A. Wright, Ph.D., who will be transitioning from Chairman of the Board to Lead Director. "We also want to thank Dr. Aiping Young for her unwavering service as the former President and Chief Executive Officer," said Dr. Wright. "Dr. Young will continue to contribute to the cutting-edge research and operational activities as the President and Chief Operating Officer of the Company."
"The outstanding research team at Lorus has built a staged pharmaceutical pipeline of innovative therapies to address the needs of patients with cancer," said Dr. Rice. "I look forward to working with the team to expeditiously advance these programs, and the Board has provided the latitude for us to explore all available options to maximize shareholder value."
Dr. Rice was most recently President, CEO and Chairman of the Board at Cylene Pharmaceuticals, Inc., a clinical-stage private company where he led the strategic and financing activities to design and develop small molecule therapeutics to exploit CK2-driven pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Prior to Cylene, Dr. Rice was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc., served as Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine.
Lorus also announced today the addition of Daniel D. Von Hoff, M.D. as the Company's Senior Vice President of Medical Affairs. Dr. Von Hoff is the Physician-in-Chief, Distinguished Professor at Translational Genomics Research Institute in Phoenix, Arizona and Professor of Medicine, Mayo Clinic, Scottsdale, AZ. He and his colleagues led the development of many cancer agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel and others. Dr. Von Hoff has published more than 629 papers and 137 book chapters, 1066 abstracts, is a founder of ILEX(TM) Oncology, and is the editor and past editor of multiple cancer publications. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO) and served on President Bush's National Cancer Advisory Board, as President of the American Association for Cancer Research and on the board of ASCO.